Literature DB >> 8627675

Identification and mapping of functional domains on human T-cell lymphotropic virus type 1 envelope proteins by using synthetic peptides.

Y Sagara1, Y Inoue, H Shiraki, A Jinno, H Hoshino, Y Maeda.   

Abstract

To identify the regions that are important in human T-cell leukemia virus type 1 (HTLV-1) envelope function, we synthesized 23 kinds of peptides covering the envelope proteins and examined the inhibitory effect of each peptide on syncytium formation induced by HTLV-1-bearing cells. Of the 23 synthetic peptides, 2, corresponding to amino acids 197 to 216 on gp46 and 400 to 429 on gp21, inhibited syncytium formation induced by HTLV-1-bearing cells but did not affect syncytium formation induced by human immunodeficiency virus type 1-producing cells. The peptide concentrations giving 50% inhibition of syncytium formation for gp46 197 to 216 and gp21 400 to 429 were 14.9 and 6.0 microM, respectively. A syncytium formation assay with overlapping synthetic peptides containing amino acids 175 to 236 and 391 to 448 of the envelope proteins showed that syncytium formation was inhibited by peptides that contained the amino acid sequences 197 to 205 (Asp-His-Ile-Leu-Glu-Pro-Ser-Ile-Pro) and 397 to 406 (Gln-Glu-Gln-Cys-Arg-Phe- Pro-Asn-Ile-Thr). These observations suggest that the two regions corresponding to amino acids 197 to 216 and 400 to 429 are involved] in HTLV-1 envelope function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627675      PMCID: PMC189978     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  HTLV-1 envelope sequences from Brazil, the Caribbean, and Romania: clustering of sequences according to geographic origin and variability in an antibody epitope.

Authors:  T F Schulz; M L Calabrò; J G Hoad; C V Carrington; E Matutes; D Catovsky; R A Weiss
Journal:  Virology       Date:  1991-10       Impact factor: 3.616

2.  Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.

Authors:  Y Tanaka; L Zeng; H Shiraki; H Shida; H Tozawa
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

3.  Detection of antibodies to human T-lymphotropic virus type I by using synthetic peptides.

Authors:  N Kuroda; Y Washitani; H Shiraki; H Kiyokawa; M Ohno; H Sato; Y Maeda
Journal:  Int J Cancer       Date:  1990-05-15       Impact factor: 7.396

4.  Limited sequence variation in human T-lymphotropic virus type 1 isolates from North American and African patients.

Authors:  E Paine; J Garcia; T C Philpott; G Shaw; L Ratner
Journal:  Virology       Date:  1991-05       Impact factor: 3.616

5.  Linear antigenic regions of the structural proteins of human T-cell lymphotropic virus type I detected by enzyme-linked immunosorbent assays using synthetic peptides as antigens.

Authors:  Y Washitani; N Kuroda; H Shiraki; Y Itoyama; H Sato; K Ohshima; H Kiyokawa; Y Maeda
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

6.  Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1.

Authors:  M Kuroki; M Nakamura; Y Itoyama; Y Tanaka; H Shiraki; E Baba; T Esaki; T Tatsumoto; S Nagafuchi; S Nakano
Journal:  J Immunol       Date:  1992-08-01       Impact factor: 5.422

7.  Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.

Authors:  T J Palker; E R Riggs; D E Spragion; A J Muir; R M Scearce; R R Randall; M W McAdams; A McKnight; P R Clapham; R A Weiss
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

8.  Neutralizing activity of human antibodies against the structural protein of human T-cell lymphotropic virus type I.

Authors:  Y Inoue; N Kuroda; H Shiraki; H Sato; Y Maeda
Journal:  Int J Cancer       Date:  1992-12-02       Impact factor: 7.396

9.  Comparison between strains of human T lymphotropic virus type I isolated from inhabitants of the Solomon Islands and Papua New Guinea.

Authors:  R Yanagihara; V R Nerukar; A B Ajdukiewicz
Journal:  J Infect Dis       Date:  1991-09       Impact factor: 5.226

10.  Inhibition of infection with human immunodeficiency virus type 1 by sulfated gangliosides.

Authors:  A Handa; H Hoshino; K Nakajima; M Adachi; K Ikeda; K Achiwa; T Itoh; Y Suzuki
Journal:  Biochem Biophys Res Commun       Date:  1991-02-28       Impact factor: 3.575

View more
  21 in total

1.  Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins.

Authors:  B Kobe; R J Center; B E Kemp; P Poumbourios
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

Review 2.  Structural and functional anatomy of the globular domain of complement protein C1q.

Authors:  Uday Kishore; Rohit Ghai; Trevor J Greenhough; Annette K Shrive; Domenico M Bonifati; Mihaela G Gadjeva; Patrick Waters; Mihaela S Kojouharova; Trinad Chakraborty; Alok Agrawal
Journal:  Immunol Lett       Date:  2004-09       Impact factor: 3.685

3.  Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway.

Authors:  Makoto Ujike; Hiroki Nishikawa; Akira Otaka; Naoki Yamamoto; Norio Yamamoto; Masao Matsuoka; Eiichi Kodama; Nobutaka Fujii; Fumihiro Taguchi
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

4.  Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association.

Authors:  A L Maerz; H E Drummer; K A Wilson; P Poumbourios
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Human CD4+ T lymphocytes recognize a highly conserved epitope of human T lymphotropic virus type 1 (HTLV-1) env gp21 restricted by HLA DRB1*0101.

Authors:  B Kitze; K Usuku; Y Yamano; S Yashiki; M Nakamura; T Fujiyoshi; S Izumo; M Osame; S Sonoda
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

6.  Conformation-specific antibodies targeting the trimer-of-hairpins motif of the human T-cell leukemia virus type 1 transmembrane glycoprotein recognize the viral envelope but fail to neutralize viral entry.

Authors:  Antonis Mirsaliotis; Kulpash Nurkiyanova; Daniel Lamb; Jenny M Woof; David W Brighty
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

7.  Human T-cell leukemia virus type 1 receptor expression among syncytium-resistant cell lines revealed by a novel surface glycoprotein-immunoadhesin.

Authors:  S R Jassal; R G Pöhler; D W Brighty
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Trypsin-sensitive and -resistant components in human T-cell membranes required for syncytium formation by human T-cell lymphotropic virus type 1-bearing cells.

Authors:  Y Sagara; C Ishida; Y Inoue; H Shiraki; Y Maeda
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

9.  An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein.

Authors:  Josefina D Piñón; Sharon M Kelly; Nicholas C Price; Jack U Flanagan; David W Brighty
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

10.  Analysis of functional conservation in the surface and transmembrane glycoprotein subunits of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2.

Authors:  A R Rosenberg; L Delamarre; A Preira; M C Dokhélar
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.